{
    "clinical_study": {
        "@rank": "102508", 
        "arm_group": [
            {
                "arm_group_label": "LEE011 + letrozole", 
                "arm_group_type": "Experimental", 
                "description": "LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating), letrozole - 2.5 mg/day"
            }, 
            {
                "arm_group_label": "BYL719 + letrozole", 
                "arm_group_type": "Experimental", 
                "description": "BYL719 - daily (dose escalating), letrozole - 2.5 mg/day"
            }, 
            {
                "arm_group_label": "LEE011 + BYL719 + letrozole", 
                "arm_group_type": "Experimental", 
                "description": "LEE011 - 28 day cycles (21 days followed by a 7 day break -dose escalating), BYL719 - daily (dose escalating), letrozole 2.5 mg/day"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to inform the future clinical development of the two\n      investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719\n      (PI3K-alpha inhibitor).\n\n      This is a multi-center, open-label Phase Ib/II study. The Phase Ib portion of the study is a\n      dose escalation to estimate the MTD and/or RP2D for three regimens: two double combinations,\n      LEE011 with letrozole and BYL719 with letrozole, followed by the triple combination of\n      LEE011 + BYL719 with letrozole.\n\n      The  Phase Ib will be followed by a randomized Phase II study to assess the preliminary\n      anti-tumor activity of the two double combination regimens (LEE011+letrozole and\n      BYL719+letrozole) versus the triple combination (LEE011+BYL719 with letrozole) and to\n      further evaluate their safety in patients with ER+/HER2- locally advanced or metastatic\n      breast cancer.\n\n      Approximately 300 adult women with ER+/HER2- locally advanced or metastatic breast cancer\n      will be enrolled."
        }, 
        "brief_title": "Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This study will investigate the combination of LEE011 (CDK4/6i) and BYL719 (PI3K-alpha-i)\n      with letrozole in patients with ER+/HER2- breast cancer (BC).  In Phase Ib there are three\n      dose escalation cohorts that will enroll sequentially.  Arm 1 is the escalation of the\n      double combination LEE011 + letrozole; Arm 2 is the dose escalation of the double\n      combination of BYL719 + letrozole.  The two double combinations will be followed by Arm 3\n      the dose escalation of the triple combination of LEE011 + BYL719  with letrozole.  The three\n      dose escalation cohorts will enroll patients with ER+/HER2- BC with any number of prior\n      lines of endocrine therapy with up to one prior cytotoxic regimen in the metastatic or\n      locally advanced setting. Pre- and post-treatment tumor biopsies are required in the three\n      dose escalation cohorts.  Once the RP2D/MTD of each double regimen is identified, dose\n      expansion cohorts of each of these two combinations will open and will enroll in the\n      first-line setting to confirm the doses selected in each double combination; archival tumor\n      tissue is required in these cohorts, although pre- and post-biopsies in these expansion\n      cohorts are optional.\n\n      Once the dose is identified for the triple combination, the randomized, three-arm Phase II\n      portion of the study will commence enrollment.  This part of the trial will enroll in the\n      first line setting in patients with ER+/HER2- BC and will randomize patients in a 1:1:1\n      ratio to either double regimen (LEE011+letrozole or BYL719 +letrozole) or the triple\n      combination of LEE011+BYL719 with letrozole."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Postmenopausal, Estrogen-receptor positive breast cancer\n\n          -  Phase Ib dose escalation only: Any number of prior lines of endocrine therapy is\n             allowed with the exception of cytotoxic therapy which is limited to one prior line\n             administered in the metastatic or locally advanced setting.\n\n          -  Phase Ib dose expansion in Arms 1 and 2 and Phase II: No prior systemic treatment in\n             the metastatic setting.\n\n        Exclusion Criteria:\n\n          -  HER2-overexpression in the patient's tumor tissue\n\n          -  Patients with active CNS or other brain metastases\n\n          -  Major surgery within 2 weeks\n\n          -  Acute or chronic pancreatitis\n\n          -  Bilateral diffuse lymphangitic carcinomatosis\n\n          -  Another malignancy within 3 years\n\n          -  Receiving hormone replacement therapy that cannot be discontinued\n\n          -  Impaired cardiac function\n\n          -  Patients with clinically manifest diabetes mellitus (treated and/or clinical signs or\n             with fasting glucose \u2265 140 mg/dL / 7.8 mmol/L), history of gestational diabetes\n             mellitus or documented steroid-induced diabetes mellitus.\n\n          -  Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01872260", 
            "org_study_id": "CLEE011X2107"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LEE011 + letrozole", 
                    "LEE011 + BYL719 + letrozole"
                ], 
                "description": "LEE011 - 28 day cycles (21 days followed by a 7 day break)", 
                "intervention_name": "LEE011", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "LEE011 + letrozole", 
                    "BYL719 + letrozole", 
                    "LEE011 + BYL719 + letrozole"
                ], 
                "description": "Letrozole 2.5 mg/day", 
                "intervention_name": "Letrozole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "BYL719 + letrozole", 
                    "LEE011 + BYL719 + letrozole"
                ], 
                "description": "Daily", 
                "intervention_name": "BYL719", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Letrozole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "estrogen-receptor positive", 
        "lastchanged_date": "February 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "anickel@hogonc.com", 
                    "last_name": "Amanda Nickel", 
                    "phone": "+1 479 872 8130"
                }, 
                "facility": {
                    "address": {
                        "city": "Fayetteville", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72703"
                    }, 
                    "name": "Highlands Oncology Group Dept of Highlands Oncology Grp"
                }, 
                "investigator": {
                    "last_name": "Joseph Thaddeus Beck", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Virginia.naaessig@cshs.org", 
                    "last_name": "Virginia Naessig", 
                    "phone": "310-248-6733"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Cedars Sinai Medical Center SC-5"
                }, 
                "investigator": {
                    "last_name": "William Audeh", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ddmiller@ucsd.edu", 
                    "last_name": "Deborah Miller", 
                    "phone": "858-822-5352"
                }, 
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "University of California at San Diego, Moores Cancer Ctr Dept. of Moores Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Teresa Helsten", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "fiermontep@cc.ucsf.edu", 
                    "last_name": "Paula Fiermonte", 
                    "phone": "415-514-6245"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94101"
                    }, 
                    "name": "University of California San Francisco Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Pamela Munster", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "simin.hassani@moffitt.org", 
                    "last_name": "Sumin Hassani", 
                    "phone": "813-745-1807"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center & Research Institute H. Lee Moffitt SC"
                }, 
                "investigator": {
                    "last_name": "Roohi Ismail-Khan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "tthorne@iuhealth.org", 
                    "last_name": "Tracy Thorne", 
                    "phone": "574-364-2649"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Health Goshen Center for Cancer Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Daniel Bruetman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Jward3@kumc.edu", 
                    "last_name": "Jan Ward", 
                    "phone": "913-945-5792"
                }, 
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "University of Kansas Cancer Center Univ Kansas 2"
                }, 
                "investigator": {
                    "last_name": "Qamar J. Khan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sclegg@partners.org", 
                    "last_name": "Stephanie Clegg"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital SC-5"
                }, 
                "investigator": {
                    "last_name": "Dejan Juric", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dan Chen", 
                    "phone": "603-650-6425"
                }, 
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756"
                    }, 
                    "name": "Dartmouth Hitchcock Medical Center Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Peter Kaufman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "krierci@ucmail.uc.edu", 
                    "last_name": "Katie Krier", 
                    "phone": "513-584-0429"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "University of Cincinnati Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "John Morris", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "barbara.calabro@UHhospitals.org", 
                    "last_name": "Barbara Calabro", 
                    "phone": "216-844-4722"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106-5000"
                    }, 
                    "name": "Case Western Reserve SC"
                }, 
                "investigator": {
                    "last_name": "Paula Silverman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sioux Falls", 
                        "country": "United States", 
                        "state": "South Dakota", 
                        "zip": "57104"
                    }, 
                    "name": "Sanford Research Dept of Oncology"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "danielle.carroll@scresearch.net", 
                    "last_name": "Danielle Carroll", 
                    "phone": "615-329-7432"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute SCRI SC"
                }, 
                "investigator": {
                    "last_name": "Erika P Hamillton", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Jamica.p.quarles@vanderbilt.edu", 
                    "last_name": "Jamica K Quarles", 
                    "phone": "615-936-1164"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt University Medical Center Vanderbilt - Thompson Ln"
                }, 
                "investigator": {
                    "last_name": "Ingrid Mayer", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "taqi.mohammad@mckesson.com", 
                    "last_name": "Taqi Mohammad", 
                    "phone": "+1 214 370 1915"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Texas Oncology, P.A. Texas Oncology - Sammons"
                }, 
                "investigator": {
                    "last_name": "Carlos Roberto Becerra", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "bmartin@tmhs.org", 
                    "last_name": "Brianne Martin", 
                    "phone": "713-441-6011"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Methodist Hospital / Methodist Cancer Center Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Angel Rodriguez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "stubblefielc@uthscsa.edu", 
                    "last_name": "Cody Stubblefield", 
                    "phone": "210-450-1789"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Cancer Therapy & Research Center / UT Health Science Center Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Anand B Karnad", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "bmcguire@nwmsonline.com", 
                    "last_name": "Elizabeth McGuire-Robinson", 
                    "phone": "253-428-8752"
                }, 
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98405"
                    }, 
                    "name": "Northwest Medical Specialties Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Sibel Blau", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Westmead", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2145"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malvern", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3144"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parkville", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3050"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perth", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6005"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Herblain cedex", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Petach Tikva", 
                        "country": "Israel", 
                        "zip": "49100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel-Aviv", 
                        "country": "Israel", 
                        "zip": "64239"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Meldola", 
                        "country": "Italy", 
                        "state": "FC", 
                        "zip": "47014"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monza", 
                        "country": "Italy", 
                        "state": "MB", 
                        "zip": "20900"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Modena", 
                        "country": "Italy", 
                        "state": "MO", 
                        "zip": "41100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pisa", 
                        "country": "Italy", 
                        "state": "PI", 
                        "zip": "56126"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "state": "TO", 
                        "zip": "10126"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "France", 
                "Hong Kong", 
                "Israel", 
                "Italy", 
                "Spain"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of Dose limiting toxicities (DLTs) - Phase lb only", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "description": "PFS as per RECIST v1.1 (by local investigator assessment)", 
                "measure": "Progression free survival (PFS) - Phase ll only", 
                "safety_issue": "No", 
                "time_frame": "Average 17 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01872260"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse Events (AEs), serious AEs (SAEs), changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, reductions and dose intensity", 
                "measure": "Safety and tolerability of LEE011 in combination with letrozole, BYL719 in combination with letrozole, and the triple combination of LEE011 +BYL719 with letrozole", 
                "safety_issue": "Yes", 
                "time_frame": "Average 24 months"
            }, 
            {
                "description": "To characterize the PK profiles of LEE011, BYL719, and letrozole when used in combination as well as to evaluate any other clinically significant metabolites that may be identified.", 
                "measure": "Plasma concentration-time profiles of LEE011, BYL719 and letrozole", 
                "safety_issue": "No", 
                "time_frame": "Average 24 months"
            }, 
            {
                "description": "ORR is defined as the proportion of patients with a best overall response of complete response or partial response.", 
                "measure": "Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Average 24 months"
            }, 
            {
                "description": "DOR is calculated as the time from the date of first documented response (complete response (CR) or partial response (PR)) to the first documented date of progression or death due to underlying cancer.", 
                "measure": "Duration of Response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "Average 24 months"
            }, 
            {
                "description": "PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause.", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Average 24 months"
            }, 
            {
                "description": "OS is defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last known date patient alive.", 
                "measure": "Overall Survival (OS) - Phase ll only", 
                "safety_issue": "No", 
                "time_frame": "Average 24 months"
            }, 
            {
                "description": "To characterize the PK profiles of LEE011, BYL719, and letrozole when used in combination as well as to evaluate any other clinically significant metabolites that may be identified.", 
                "measure": "Pharmacokinetics (PK) parameters, including but not limited to AUCtau, Cmin, Cmax, Tmax, accumulation ratio (Racc)", 
                "safety_issue": "No", 
                "time_frame": "Average 24 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}